» Articles » PMID: 36262899

Recurrence of Thrombotic Thrombocytopenic Purpura After Vaccination with MRNA-1273 COVID-19 Vaccine

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by thrombocytopenia, microangiopathic hemolytic anemia, and ischemic organ damage. Several cases of TTP associated with administration of COVID-19 vaccines have been reported. We report a case of a 63-year-old woman with a past medical history of hypertension, diabetes mellitus, chronic kidney disease, HIV infection, and remote history of TTP who presented with several days of shortness of breath on exertion, chest tightness, low-grade fever, and bruising thirty-three days after receiving the second dose of the mRNA-1273 COVID-19 vaccine. Thrombocytopenia and hemolytic anemia with schistocytes were noted on testing, and ADAMTS13 activity was <5%. Temporizing treatment with fresh frozen plasma was started immediately on presentation, and treatment was continued with daily therapeutic plasma exchange and corticosteroids. TTP should be considered in patients who present with thrombocytopenia after COVID-19 vaccination, especially if there is a past history of TTP.

Citing Articles

Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac.

Long Z, Jiang S, Xin H, Zhang L, Lu R, Liu F Front Med. 2024; 18(4):744-751.

PMID: 38958922 DOI: 10.1007/s11684-023-1054-2.


Thrombotic Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccination in a Patient With Multiple Myeloma: Case Report and Literature Review.

Dan C, Sahai A, Dan D, Sahai A, Trehan R Cureus. 2023; 15(10):e46784.

PMID: 37954740 PMC: 10633882. DOI: 10.7759/cureus.46784.


Recurrence of Thrombotic Thrombocytopenic Purpura After COVID-19 Vaccination: Correspondence.

Mungmunpuntipantip R, Wiwanitkit V J Community Hosp Intern Med Perspect. 2023; 13(1):77.

PMID: 36817296 PMC: 9924626. DOI: 10.55729/2000-9666.1154.

References
1.
Willis M, Bandarenko N . Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease?. Semin Thromb Hemost. 2006; 31(6):700-8. DOI: 10.1055/s-2005-925476. View

2.
Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

3.
Chamarti K, Dar K, Reddy A, Gundlapalli A, Mourning D, Bajaj K . Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances. Cureus. 2021; 13(7):e16619. PMC: 8381440. DOI: 10.7759/cureus.16619. View

4.
Kirpalani A, Garabon J, Amos K, Patel S, Sharma A, Lalgudi Ganesan S . Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab. Br J Haematol. 2021; 196(1):e11-e14. PMC: 8444813. DOI: 10.1111/bjh.17782. View

5.
Ruhe J, Schnetzke U, Kentouche K, Prims F, Baier M, Herfurth K . Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine. Ann Hematol. 2021; 101(3):717-719. PMC: 8311064. DOI: 10.1007/s00277-021-04584-y. View